David A. Isenberg

Dr. David A. Isenberg

orcid

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2012 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MPMichelle Petri
Michelle Petri
AOAna‐Maria Orbai
Ana‐Maria Orbai
GAGraciela S. Alarcón
Graciela S. Alarcón
CGCaroline Gordon
Caroline Gordon
JMJoan T. Merrill
Joan T. Merrill
LMLaurence S. Magder
Laurence S. Magder
Objective: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.Methods: The classification criteria were derived from a set of 702 expert‐rated patient scenarios. Recursive partitioning was used to derive an initial rule that was simplified and refined based on SLICC physician consensus. The SLICC group validated the classification criteria in a new validation sample of 690 new expert‐rated patient scenarios.Results: Seventeen criteria were identified. In the derivation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (49 versus 70; P = 0.0082) and had greater sensitivity (94% versus 86%; P < 0.0001) and equal specificity (92% versus 93%; P = 0.39). In the validation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (62 versus 74; P = 0.24) and had greater sensitivity (97% versus 83%; P < 0.0001) but lower specificity (84% versus 96%; P < 0.0001).Conclusion: The new SLICC classification criteria performed well in a large set of patient scenarios rated by experts. According to the SLICC rule for the classification of SLE, the patient must satisfy at least 4 criteria, including at least one clinical criterion and one immunologic criterion OR the patient must have biopsy‐proven lupus nephritis in the presence of antinuclear antibodies or anti–double‐stranded DNA antibodies.

1 March 1996 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
DGDafna Gladman
Dafna Gladman
EGEllen Ginzler
Ellen Ginzler
CGCharles Goldsmith
Charles Goldsmith
PFPaul Fortin
Paul Fortin
MLMatthew Liang
Matthew Liang
AZAsad Zoma
Asad Zoma
Objective. To develop and perform an initial validation of a damage index for systemic lupus erythematosus (SLE).Methods. A list of items considered to reflect damage in SLE was generated through a nominal group process. A consensus as to which items to be included in an index was reached, together with rules for ascertainment. Each center submitted 2 assessments, 5 years apart, on 2 patients with active and 2 with inactive disease, of whom 1 had increased damage and the other had stable disease. Analysis of variance was used to test the factors physician, time, amount of damage, and activity status.Results. Nineteen physicians completed the damage index on 42 case scenarios. The analysis revealed that the damage index could identify changes in damage seen in patients with both active and inactive disease. Patients who had active disease at both time points had a higher increase in damage. There was good agreement among the physicians on the assessment of damage in these patients.Conclusion. This damage index for SLE records damage occurring in patients with SLE regardless of its cause. The index was demonstrated to have content, face, criterion, and discriminant validity.

28 February 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
ARAnisur Rahman
Anisur Rahman
DIDavid A. Isenberg
David A. Isenberg
Systemic lupus erythematosus has many guises, but the unifying feature is the presence of antibodies against double-stranded DNA in almost all patients. This review provides data that show that such autoantibodies cause the renal lesions of systemic lupus erythematosus, and it emphasizes the importance of histones, histone fragments, and other nuclear autoantigens.

1 January 2010 in Immunity
Verified
Journal Article
Closed access
PBPaul A. Blair
Paul A. Blair
LNLina Yassin Noreña
Lina Yassin Noreña
FFFabian Flores-Borja
Fabian Flores-Borja
DRDavid J. Rawlings
David J. Rawlings
DIDavid A. Isenberg
David A. Isenberg
CMClaudia Mauri
Claudia Mauri

28 December 2009 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
JMJoan T. Merrill
Joan T. Merrill
CNC. Michael Neuwelt
C. Michael Neuwelt
DWDaniel J. Wallace
Daniel J. Wallace
JSJoseph C. Shanahan
Joseph C. Shanahan
KLKevin M. Latinis
Kevin M. Latinis
PBPaul G. Brunetta
Paul G. Brunetta
Objective: B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with moderately‐to‐severely active extrarenal SLE.Methods: Patients entered with ≥1 British Isles Lupus Assessment Group (BILAG) A score or ≥2 BILAG B scores despite background immunosuppressant therapy, which was continued during the trial. Prednisone was added and subsequently tapered. Patients were randomized at a ratio of 2:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182.Results: In the intent‐to‐treat analysis of 257 patients, background treatment was evenly distributed among azathioprine, mycophenolate mofetil, and methotrexate. Fifty‐three percent of the patients had ≥1 BILAG A score at entry, and 57% of the patients were categorized as being steroid dependent. No differences were observed between placebo and rituximab in the primary and secondary efficacy end points, including the BILAG‐defined response, in terms of both area under the curve and landmark analyses. A beneficial effect of rituximab on the primary end point was observed in the African American and Hispanic subgroups. Safety and tolerability were similar in patients receiving placebo and those receiving rituximab.Conclusion: The EXPLORER trial enrolled patients with moderately‐to‐severely active SLE and used aggressive background treatment and sensitive cutoffs for nonresponse. No differences were noted between placebo and rituximab in the primary and secondary end points. Further evaluation of patient subsets, biomarkers, and exploratory outcome models may improve the design of future SLE clinical trials.

26 July 2004 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MEMichael R. Ehrenstein
Michael R. Ehrenstein
JEJamie G. Evans
Jamie G. Evans
ASAnimesh Singh
Animesh Singh
SMSamantha Moore
Samantha Moore
GWGary Warnes
Gary Warnes
CMClaudia Mauri
Claudia Mauri
Engagement of the TCR triggers sustained Ca2+ entry through Ca2+ release-activated Ca2+ (CRAC) channels, which helps drive gene expression underlying the T cell response to pathogens. The identity and activation mechanism of CRAC channels at a molecular level are unknown. We have analyzed ion channel expression and function in T cells from SCID patients which display 1–2% of the normal level of Ca2+ influx and severely impaired T cell activation. The lack of Ca2+ influx is not due to deficient regulation of Ca2+ stores or expression of several genes implicated in controlling Ca2+ entry in lymphocytes (kcna3/Kv1.3, kcnn4/IKCa1, trpc1, trpc3, trpv6, stim1). Instead, electrophysiologic measurements show that the influx defect is due to a nearly complete absence of functional CRAC channels. The lack of CRAC channel activity is correlated with diminished voltage sensitivity and slowed activation kinetics of the voltage-dependent Kv1.3 channel. These results demonstrate that CRAC channels provide the major, if not sole, pathway for Ca2+ entry activated by the TCR in human T cells. They also offer evidence for a functional link between CRAC and Kv1.3 channels, and establish a model system for molecular genetic studies of the CRAC channel.